Gentian develops and produces diagnostic tests for clinical chemistry, focusing on improving efficiency for laboratories and patients.

Gentian Diagnostics 

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.

Gentian Diagnostics ASA

Gentian

Gentian Diagnostics – a global medical diagnostics company – develops and manufactures high quality, in vitro diagnostic (IVD) reagents for a wide range of clinical chemistry analysers. Our product lines of laboratory tests, for diverse medical conditions, improve accuracy and provide faster results, for both human and veterinary healthcare. 

Gentian Diagnostics serves the global market for human and veterinary medical diagnostic tests via our OEM partners and key distributors. The Gentian HQ and production facility is in Moss, Norway. We also have a representative office in China and the distribution subsidiaries: Gentian USA, Inc. and Gentian Diagnostics AB (Sweden). 

Our interdisciplinary and international teams work on global solutions to ensure #DiagnosticEfficiency.   

Gentian'S turbidimetric immunoassays: GCAL® PLASMA AND SERUM CALPROTECTIN – CYSTATIN C – CANINE CRP- RETINOL-BINDING PROTEIN - SARS-CoV-2 TOTAL ANTIBODY

Connect with us:
Web: www.gentian.com
E-mail: marketing@gentian.com
Facebook: facebook.com/GentianDiagnostics
Twitter: twitter.com/GentianDiagnost
Twitter: twitter.com/Cystatin_C
Instagram: instagram.com/gentiandiagnostics/

#DiagnosticEfficiency👩🏼‍🔬 Exciting #NTproBNP news from Gentian at #ADLM2024 last week! 🚀 Our poster, "Development and Diagnostic Utility of Immunoturbidimetric NT-proBNP Assay," showcased our innovative approach targeting non-glycosylated regions of the molecule to measure total NT-proBNP accurately. 

Unlike most commercial tests that underestimate NT-proBNP levels, our prototype demonstrated excellent analytical performance, confirming its potential to revolutionise NT-proBNP measurements and enhance accessibility on #clinicalchemistry platforms. Read more👉https://lnkd.in/dU42JGiv

We are here! Excited for day 1 at #ADLM2024! Come by booth #3201 say hello #diagnosticefficiency

At #ADLM2024 and interested to learn more about the biomarker #calprotectin (S100A8/A9 protein)?  Circulating calprotectin has been shown to be involved in various inflammatory conditions. Discover its potential at our poster B-068: "Plasma Calprotectin as an Index of Draining Tunnel Formation in Hidradenitis Suppurativa (HS)," where we present calprotectin as a biomarker for assessing disease severity in HS patients.

Learn more about circulating calprotectin and HS 👉 https://lnkd.in/dBnnAHmS

Don’t miss the opportunity to meet Gentian’s CSO, Aleksandra Havelka Havelka, and Global Product Manager, Elin Godager, at the poster session on Wednesday, July 31, from 1:30 to 2:30 p.m., or visit us at #booth3201 to learn more about this novel biomarker.

#ADLM2024 Gentian's turbidimetric #NTproBNP assay, now in the verification phase, will uniquely target non-glycosylated areas of the molecule, and therefore measure the total amount of NT-proBNP, unlike most current commercial tests which bind to glycosylated regions of NT-proBNP molecule. 

Learn more about Nt-proBNP and the assay development👉 https://lnkd.in/ddQxPZ4y

At #ADLM in Chicago? Don't miss the opportunity to delve deeper into this ground-breaking development and engage with us at the poster session tomorrow Tuesday 30 July from 1:30 to 2:30 p.m.: A-010. “Development and diagnostic utility of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP”.

Meet Gentian’s CSO, Aleksandra Mandic Havelka , and Global Product Manager, Elin Godager, at the poster session or visit us at #booth3201 to learn more about #DiagnosticEfficiency👩🏼‍🔬 and Gentian's products

The Gentian team has a great time at #ADLM2024! see you at booth #3201 to discuss #diagnosticefficiency and learn more about our assays and #DiagnosticEfficiency👩🏼‍🔬 #CystatinC

#DiagnosticEfficiency👩🏼‍🔬 Going to #ADLM2024? Learn more about Gentian's turbidimetric Retinol-Binding Protein #RBP at booth #3201 See you next week! Read more about the assay👉https://lnkd.in/d4NADTcp

GENT

COM:GENTIAN

Gentian

Last Close

52.50

30/08 14:27

Market Cap

863.65M

Beta: -

Volume Today

11.30K

Avg: -

locale

market

industry

website

linkedin

founding date

ipo date

investor of

Metrics